This site is intended for U.S. healthcare professionals.
Menu
Close
Home
About
Storage and handling
Vial sizes and NDC numbers
Purchasing Information
Biochemical composition and manufacturing
Dosing & Infusion Rates
CIDP
Dosing and administration
Infusion rate chart
PI
Dosing and administration
Infusion rate chart
cITP
Dosing and administration
Infusion rate chart
Efficacy
CIDP
Study design
INCAT responder rates
Supporting efficacy endpoints
Dose adjustments
PI
Study designs
Primary endpoint, secondary endpoints, and safety assessments
cITP
Study design, primary endpoint, and secondary endpoints
Safety & Tolerability
CIDP
Adverse reactions
PI
Adverse reactions
cITP
Adverse reactions
Support
Materials
Videos
Pfizer IGuideTM
Pfizer PANZYGA Co-Pay Program for patients
Frequently asked questions
Request a representative
This text is for block level content. P tags can go in here too
** This is an optional area where footnotes can live.
The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
** This is an optional area where footnotes can live.
The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
** This is an optional area where footnotes can live.
Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.
Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving PANZYGA.
Aseptic meningitis syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion.
Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.
Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).
Monitor blood pressure prior to, during, and following PANZYGA infusion.
Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload.
PANZYGA is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent.
PI – The most common adverse reactions (≥5% study subjects) were headache, nausea, fever, fatigue, and abdominal pain.
cITP in adults – The most common adverse reactions (≥5% study subjects) were headache, fever, nausea, vomiting, dizziness, and anemia.
CIDP in adults – The most common adverse reactions reported in greater than 5% of subjects were: headache, fever, dermatitis, and blood pressure increase.
The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for PANZYGA.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
PANZYGA® is a registered trademark of Octapharma AG.
Please click here for Full Prescribing Information, including BOXED WARNING.
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.
Please see full Prescribing Information, including BOXED WARNING.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?